Over the past few decades, miR-106a has been reported to be involved in promoting the proliferation of endometrial cancer RL95-2 cells and inhibiting cell apoptosis 43, in attenuating hyperglycemia induced vascular endothelial cell dysfunction through targeting HMGB1 44, in modulation of tumor cell growth 45. This evidence concerns the gene HMGB1 and endometrial cancer.